Seralutinib

DRUG3 trials

Sponsors

GB002, Inc., Gossamer Bio USA, Inc.

Conditions

Pulmonary Arterial HypertensionPulmonary Hypertension Associated With Interstitial Lung Disease

Phase 3

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

CompletedNCT05934526

GB002, Inc.Pulmonary Arterial Hypertension

Start: 2023-12-28End: 2025-12-22Updated: 2026-05-19

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

RecruitingNCT06274801

Gossamer Bio USA, Inc.Pulmonary Arterial Hypertension

Start: 2024-09-03End: 2026-12-01Target: 330Updated: 2026-07-29

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

SuspendedNCT07181382

GB002, Inc.Pulmonary Hypertension Associated With Interstitial Lung Disease

Start: 2026-02-01End: 2028-12-01Target: 480Updated: 2026-03-19

Related Papers

Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study

Advances in Therapy2025-08-111 citations